Free tool
FAERS Monitor: Neurolite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020256 or its brand name (Neurolite, Technetium Tc-99m Bicisate Kit). Reports on generic versions are filed under their own applications.
Reports
23
Serious
11
48% of reports
Hospitalization
7
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective8
- product preparation error5
- radioisotope scan abnormal3
- adverse event1
- anaemia1
- anaphylactic shock1
- arthralgia1
- blood pressure decreased1
- chills1
- cholecystitis1
- cholelithiasis1
- cold sweat1
- confusional state1
- decreased appetite1
- depression1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radioisotope scan abnormalSignal | 3 | 3900.8 | 1354.4 | 8,088 |
| product preparation errorSignal | 5 | 222.6 | 102.5 | 893 |
| cholecystitis | 1 | 76.8 | 11.3 | 18 |
| cold sweat | 1 | 51.9 | 7.6 | 12 |
| anaphylactic shock | 1 | 35.5 | 5.2 | 8 |
| cholelithiasis | 1 | 27.9 | 4.1 | 6 |
| blood pressure decreased | 1 | 13.8 | 2.0 | 3 |
| adverse event | 1 | 9.9 | 1.5 | 2 |
| chills | 1 | 7.8 | 1.1 | 1 |
| confusional state | 1 | 5.7 | 0.8 | 1 |
| drug ineffectiveSignal | 8 | 5.6 | 3.2 | 27 |
| anaemia | 1 | 4.8 | 0.7 | 0 |
| depression | 1 | 4.0 | 0.6 | 0 |
| decreased appetite | 1 | 3.9 | 0.6 | 0 |
| arthralgia | 1 | 2.2 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.